QCL demonstrates success in early phase pharmaceutical development. Dr Emily Ware, Director of Formulations and Manufacturing at QCL, and lead formulation Scientist, Robert Sciscento developed two dosage types avoiding first-pass metabolism in the gut. The lead dosage form was prepared for First in Human trials within 6 months of project inception. Read full case study for additional details.